Current trend of biapenem susceptibility and disc diffusion breakpoints in Enterobacterales and Pseudomonas aeruginosa
-
Published:2024-09
Issue:
Volume:51
Page:100695
-
ISSN:0255-0857
-
Container-title:Indian Journal of Medical Microbiology
-
language:en
-
Short-container-title:Indian Journal of Medical Microbiology
Author:
Bakthavatchalam Yamuna Devi,
Jennifer Lydia,
Abdullah Fiza,
Srinivasan Devishree,
Adhiya Ranjan,
Ashok Anand,
Walia Kamini,
Solaimalai DhanalakshmiORCID,
Veeraraghavan Balaji
Reference18 articles.
1. Biapenem;Perry;Drugs,2002
2. A phase 1 study of the safety, tolerability, and pharmacokinetics of biapenem in healthy adult subjects;Griffith;Antimicrob Agents Chemother,2023
3. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs;Sader;Eur J Clin Microbiol Infect Dis,1993
4. Performance standard for antimicrobial susceptibility testing,2023
5. Differences in antimicrobial susceptibility breakpoints for Pseudomonas aeruginosa, isolated from blood cultures, set by the Clinical and Laboratory Standards Institute (CLSI) and the Japanese Society of Chemotherapy;Nakamura;J Infect Chemother,2007